

CMV REFERENCES

1. Webert K. Transfusion-transmitted cytomegalovirus infection. Canadian Blood Services (internal document) 2012; 1-11.
2. Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTO). Cytomegalovirus Tested Blood Components-Position Statement. 2012; Available online at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_132965.
3. Lieberman, L. Divisional Rounds, Hematology/Oncology, Hospital for Sick Children, presentation, June 7, 2012.
4. Hevey A J. Transfusion-Transmitted Disease (TTD): Current Viral Controversies (9210-S). AABB Conference 2012; presentation handout.
5. Green ML, Leisenring W, Stachel D et al. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18: 1687-1699.
6. Nichols W, Garrett G, Price TH et. al. Transfusion transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003 101: 4195-4200.
7. Kirkland M. The precautionary principle: a double edged sword? Cell Tissue Bank 2010 Aug; 11(3):217-224.
8. Preiksaitis JK. The cytomegalovirus-"safe" blood product: Is leukoreduction equivalent to antibody screening? Transfusion Medicine Reviews 2000; Volume 14, No 2: 112-136.
9. Preiksaitis JK. Prevention of transfusion-acquired CMV infection: Is there a role for NAT? Transfusion Practice 2003; Volume 43; 302-305.
10. Thiele T, Krüger W, Zimmermann K et. al. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation. Transfusion Practice 2011; Volume 51: 2620-2626.
11. Vamvakas EC. Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transfusion Medicine Reviews 2005; Volume 19, No 3: 181-199.
12. Wu Y, Zou S, Cable R et. al. Direct assessment of cytomegalovirus transfusion-transmitted risks after universal leukoreduction. Transfusion Practice 2010; Volume 50: 776-786.
13. Seed CR, Wong J, Polizzotto MN, Keller AJ, Pink J. The residual risk of transfusion-transmitted cytomegalovirus infection associated with leucodepleted blood components. Vox Sanguinis. 2015 DOI:10.1111/Vox 12250

14. Hall S, Danby R, Osman H, Peniket A, Rocha V, Craddock C, Murphy M, Chaganti S. Transfusion in CMV seronegative T-depleted allogeneic stem cell transplant recipients with CMV-unselected blood components results in zero CMV transmissions in the era of universal leukocyte reduction: a UK dual centre experience. *Transfusion Medicine*. 2015 DOI: 10.1111
15. Preiksaitis J, Nahirniak S, Mabilangan C, Fearon M, O'Brien S. Residual risk of transfusion-acquired cytomegalovirus (CMV) infection in CMV seronegative solid organ transplant recipients receiving CMV seronegative organs and leukodepleted blood products. 2015. Presentation, Canadian Society of Transplantation.
16. Lieberman L, Devine DV, Reesink HW, Panzer S, Wong J, Raison T, Benson S, Pink J, Leitner GC, Horvath M, Compennolle V, Scuracchio PSP, Wendel S, Delage G, Nahirniak S, Dongfu X, Krusius T, Juvonen E, Sainio S, Cazenave JP, Guntz P, Kienz D, Andreu G, Morel P, Seifried E, Hourfar K, Lin CK, O'Riordan J, Raspollini E, Villa S, Rebullia P, Flanagan P, Teo D, Lam S, Ang AL, Lozano M, Sauleda S, Cid J, Perreira A, Ekermo B, Niederhauser C, Waldvogel S, Fontana S, Desborough MJ, Pawson R, Li M, Kamel H, Busch M, Qu L, Triulzi D. Prevention of transfusion-transmitted cytomegalovirus (CMV) infection: Standards of care. *Vox Sanguinis*. 2013 DOI: 10.1111/Vox 12103.
17. AABB Clinical Transfusion Medicine Committee, Heddle NM, Boeckhl M, Grossman B, Jacobson J, Kleinman S, Tobian AAR, Webert K, Wong ECC and Roback JD. AABB Committee Report: reducing transfusion-transmitted cytomegalovirus infections. *Transfusion* 2016 DOI: 10.1111/trf.13503
18. Parry HM, Zuo J, Mirajkar N, Inman C, Edwards E, Griffiths M, Pratt G and Moss P. Cytomegalovirus viral load within blood increases markedly in healthy people over the age of 70 years. *Immunity and Aging*. 2016 13:1
19. Ljungman P, Brand R, Hoek J, de la Camara R, Cordonnier C, Einsele H, Styczinski J, Ward KN and Cesaro S. Donor Cytomegalovirus Status Influences the Outcome of Allogeneic Stem Cell Transplant: A Study by the European Group for Blood and Marrow Transplantation. *CID* 2014 59:473
20. Kekre N, Tokessay M, Mallick R, McDirmid S, Huebsch L, Bredeson C, Allan D, Tay J, Tinmoth A and Sheppard D. Is Cytomegalovirus Testing of Blood Products Still Needed for Hematopoietic Stem Cell Transplant Recipients in the Era of Universal Leukoreduction? *Biol Blood Marrow Transplant* 2013 19: 1719-1724
21. Josephson CD, Caliendo AM, Easley KA, Knexvic A, Shenvi N, Hinkes MT, Patel RM, Hilyer CD and Roback JD. Blood Transfusion and Breast Milk Transmission of Cytomegalovirus in Very Low-Birth Weight Infants A Prospective Study 2014 *JAMA Pediatr* 168 (11) 1054-1062
22. Bloch EM, Jackman RP, Lee T-H and Busch MP. Transfusion-Associated Microchimerism: The Hybrid Within. *Transfusion Medicine Reviews* 2013 27:10-20
23. Furui Y, Satake M, Uchida S, Suzuki K and Tadokoro K. Cytomegalovirus (CMV) seroprevalence in Japanese blood donors and high frequency of CMV DNA in elderly donors. *Transfusion Complications* 2013 53:2190-2197

24. Fast LD, DiLeone G and Marschner S. Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation. *Transfusion* 2011 51:1397-1403